Effect of the Adrenergic Neurone Blocker, β-TM 10, on the Depletion of Noradrenaline induced by Denervation or Reserpine

  • Hans-Martin Hennemann
  • U. Trendelenburg


  1. 1

    The noradrenaline content of the rat submaxillary gland was determined fluorimetrically as various times after sympathetic denervation as well as after the subcutaneous injection of reserpine (300 μg/kg). The effect of an adrenergic neurone blocker (β-TMIO) was compared with that of an inhibitor of monoamine oxidase (pargyline).

  2. 2

    Both βTMIO (50 mg/kg s.c. given 6 hours and repeated 12 hours after the operation) and pargyline (100 mg/kg i.p. at the operation) delayed the decline of endogenous noradrenaline observed after denervation; the delay was similar for both treatments.

  3. 3

    Both, β-TMIO (50 mg/kg s.c. 2 hours before reserpine) and pargyline (100 mg/ kg s.c. 6 hours before reserpine), caused a similar delay in the reserpine-induced decline of endogenous noradrenaline in the sympathetically decentralized gland.

  4. 4

    Reserpine induced a higher rate of depletion in normal than in decentralized glands of untreated or pargyline-pretreated rats. However, the relation of depletion rates was reversed after β-TMIO.

  5. 5

    It is concluded that the last mentioned effect is at least partly due to the adrenergic neurone blocking effect of β-TMIO. The antagonism by β-TMIO of the depleting effect of sympathetic denervation and of reserpine, on the other hand, is attributed to the ability of adrenergic neurone blocking agents to block monoamine oxidase. The results confirm earlier studies and indicate that the ability of adrenergic neurone blocking agents to block intraneuronal monoamine oxidase accounts for effects which up to now have been ascribed to their ability to prevent the release of noradrenaline by nerve impulses.



β-TM10 Adrenergic Neurone Blocker Sympathetic Denervation Noradrenaline Depletion by Reserpine Monoamine Oxidase Inhibition Pargyline 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Axelrod, J., Hertting, G., Patrick, R.W.: Inhibition of H3-norepinephrine release by monoamine oxidase inhibitors. J. Pharmacol. exp. Ther. 134, 325–328 (1961).PubMedGoogle Scholar
  2. Benmiloud, M., Euler, U. S.,: Effects of bretylium, reserpine, guanethidine and sympathetic denervation on the noradrenaline content of the rat submaxillary gland. Acta physiol. scand. 59, 34–42 (1963).PubMedCrossRefGoogle Scholar
  3. Bhagat, B.: The effect of adrenergic neurone blocking agents on the release and uptake of catecholamines by the rat heart. Arch. int. Pharmacodyn. 146, 231–237 (1963).PubMedGoogle Scholar
  4. Callingham, B.A., Cass, R.: The effect of bretylium and cocaine on noradrenaline depletion. J. Pharmacol. exp. Ther. 14, 385–389 (1962).Google Scholar
  5. Crout, J.R.: Catechol amines in urine. In: Standard Methods of Clinical Chemistry, Vol. 3, pp. 62–80. Ed.: D. Seligson. New York: Academic Press 1961.Google Scholar
  6. Furchgott, R.F., Sanchez-Garcia, P.: Inhibition of monoamine oxidase of adrenergic nerve terminals by bretylium. Pharmacologist 8, 176 (1966).Google Scholar
  7. Giachetti, A., Shore, P.A.: Monoamine oxidase inhibition in the adrenergic neuron by bretylium, debrisoquin, and other adrenergic neuronal blocking agents. Biochem. Pharmacol. 16, 237–238 (1967).CrossRefGoogle Scholar
  8. Haeusler, G., Haefely, W., Huerlimann, A.: On the mechanism of the adrenergic nerve blocking action of bretylium. Naunyn-Schmiedebergs Arch. Pharmak. 265, 260–277 (1969).CrossRefGoogle Scholar
  9. Hertting, G., Axelrod, J., Patrick, R.W.: Action of bretylium and guanethidine on the uptake and release of H3-noradrenaline. Brit. J. Pharmacol. 18, 161–166 (1962).PubMedGoogle Scholar
  10. Langer, S.Z.: The degeneration contraction of the nictitating membrane in the unanesthetized cat. J. Pharmacol. exp. Ther. 151, 66–72 (1966).PubMedGoogle Scholar
  11. Lundberg, D.: Adrenergic neuron blockers and transmitter release after sympathetic denervation studied in the conscious rat. Acta physiol. scand. 75, 415 to 426 (1969).CrossRefGoogle Scholar
  12. Malmfbrs, T., Sachs, C.: Direct studies on the disappearance of the transmitter and changes in the uptake-storage mechanism of degenerating adrenergic nerves. Acta physiol. scand. 64, 211–223 (1965).CrossRefGoogle Scholar
  13. McLean, R.A., Geus, R.G., Pasternack, J., Mattis, P.A., Ullyot, G.E.: Pharmacology of trimethyl[2-(2.6-dimethylphenoxy)propyl]trimethylammonium chloride monohydrate; compound 6890 or β-TM10. J. Pharmacol. exp. Ther. 129, 17–23 (1960).PubMedGoogle Scholar
  14. Noble, B.: Numerisches Rechnen, Bd. 88, S. 94–100. Mannheim: Bibl. Institut 1964.Google Scholar
  15. Nordenfeit, I.: Cholinesterase in the submaxillary gland of the rat after sympathetic denervation. Quart. J. Physiol. 53, 6–9 (1968).Google Scholar
  16. Pluchino, S., Orden III, L.S., van, Draskoczy, P.R., Langer, S.Z., Trendelenburg, IL: The effect of β-TM10 on the pharmacological, biochemical and morphological changes induced by denervation of the nictitating membrane of the cat. J. Pharmacol. exp. Ther. (in press).Google Scholar
  17. Ryd, G.: Protective effect of bretylium on noradrenaline stores in organs. Acta physiol. scand. 56, 90–93 (1962).PubMedCrossRefGoogle Scholar
  18. Sedvall, G.: Short term effects of reserpine on noradrenaline levels in skeletal muscle. Acta physiol. scand. 62, 101–108 (1964).PubMedCrossRefGoogle Scholar
  19. Winne, D.: Zur Auswertung von Versuchsergebnissen: Die Prüfung, ob Kurven sich in ihrem Verlauf unterscheiden. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 250, 383–396 (1965).CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1969

Authors and Affiliations

  • Hans-Martin Hennemann
    • 1
  • U. Trendelenburg
    • 1
  1. 1.Institut für Pharmakologie und Toxikologie der UniversitätWürzburgDeutschland

Personalised recommendations